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ABSTRACT 
Aim: Here, we evaluated the VEGF gene -2578C/A polymorphism as a potential susceptibility factor in colorectal cancer (CRC) 
occurrence amongst Iranian CRC patients. 
Background: Vascular endothelial growth factor (VEGF) is a key regulatory factor in angiogenesis which plays essential roles in the 
development of malignancy in colorectal cancer (CRC), as the third most prevalent cancer worldwide. 
Methods: VEGF -2578C/A polymorphism was evaluated in 200 CRC patients and 200 healthy control subjects via restriction 
fragment length polymorphism analysis.  
Results: The frequencies of CC, AC and AA genotypes among CRC patients were 22.5%, 51% and 26.5%, respectively, with their 
respective genotype frequencies at 16%, 54% and 30% in control cohorts (P=0.247). The A allele frequency among the case group 
was 52% and for control group, it was 57%. C allele frequency in case and control groups was 48% and 43%, respectively (p=0.156). 
No significant association was observed (p=0.990) between this polymorphism and CRC stage.  
Conclusion: Our findings provide limited support for the hypothesis that the -2578C/A VEGF are associated with increased risk of 
colorectal cancer in Iranian colorectal cancer patients and suggest instead that meta data studies, which have previously relied upon 
populations definitions such as ‘Asian’, should more specifically take into account country of origin when associating prognostic 
value to a given genotype. 
Keywords: Colorectal cancer, Angiogenesis, VEGF, Single nucleotide polymorphism, Vascular endothelial growth factor. 
(Please cite as: Savabkar S, Zali N, Hadizadeh M, Tavangarroosta SH, Young CH, Shojaeian F, et al. Lack of association 




  1 Colorectal cancer is the third most prevalent type of 
cancer word-wide (1-5) and is becoming a major health 
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concern in Asia (6-8). There have been several studies 
evaluating the association of single nucleotide 
polymorphisms in cancer-related genes and CRC 
susceptibility (9-14). Clinical studies have previously 
shown that the dominant angiogenesis factor in 
colorectal cancer is VEGF through mechanism such as 
promoting angiogenesis and the reproduction and 
survival of endothelial cells (15-17). VEGFA is known 
generally as VEGF (17,18). VEGF gene has been 
mapped to chromosome 6p12-p21 and is comprised of 
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8 exons and 7 introns (19,20). Increased VEGF levels 
have previously been reported in tumour cells, and the 
intensity of small vessels around tumours were directly 
related to VEGF levels (21,22). Moreover, it has been 
reported that VEGFA is overexpressed in 50% of 
colorectal cancers.  
Functional studies have shown that VEGF 
polymorphisms can modify cancer susceptibility (23-
25); - 2578A > C is associated with a higher VEGF 
expression, for example (26). Koukourakis et al. (23) 
reported the −2578C/C genotype correlated with 
reduced VEGF expression, while the −2578C/A was 
associated with higher VEGF levels in non-small cell 
lung cancers. Single nucleotide polymorphisms (SNPs) 
are a significant source of genomic heterogeneity, 
which may alter cancer susceptibility (27,28). Several 
SNPs have been identified in VEGF gene including -
2578C/A (rs699947), which is located on promoter 
region of VEGF and is known to alter VEGF protein 
expression (23,29-31). This putative polymorphism is 
shown to be associated with diabetic, CRC and breast 
cancer (29,32,33). The association of the SNPs of 
VEGF with clinical outcome of patients with 
oesophageal cancer, lung cancer and gastric cancer was 
shown previously in public data sets (23,34, 35). 
We hypothesized that these polymorphisms could also 
have an impact on CRC susceptibility. Therefore, the 
aim of the present study was to investigate whether -
2578C/A polymorphism in the VEGF gene is involved 
in the development of sporadic colorectal cancer in 
Iranian patients, and to evaluate its usefulness as a 
prognostic marker.   
 
Methods 
 Study population 
Peripheral blood samples investigated in this study 
were obtained from 200 CRC patients and 200 healthy 
subjects, between 2009 and 2011, who had been 
referred to the Research Centre for Gastroenterology 
and Liver Diseases (RCGLD), Shahid Beheshti 
University of Medical Sciences (Tehran, Iran). Written 
informed consent for this study was received from 
patients and ethics approval was granted by the ethics 
committee of the Gastroenterology and Liver Diseases 
Research Centre, Shahid Beheshti University of 
Medical Sciences, Tehran, Iran. 
All patients were histologically diagnosed as being 
positive for colorectal cancer at the RCGLD. The 
control group included individuals who referred to this 
centre for screening purposes and whose negative 
colonoscopy procedure approved that they are not 
susceptible to CRC. The parameters of age, gender and 
cigarette smoking status were collected from patients 
and control groups. The stage of CRC was also 
determined in the patient group. The diagnosis and 
staging of colorectal cancer were assessed according to 
the WHO classifications after confirmation by 
accredited pathologists. The cases were then submitted 
for genetic studies. 
Genotyping 
Total genomic DNA was extracted from peripheral 
blood using the Salting Out method (36). Primer 
sequences of the VEGF gene were designed with Gene 
Runner software (version 4.0.9.68 Beta). The PCR 
primers used to amplify the promoter region of VEGF 
gene included the following: Forward: 5'- 
ACTAGTGCACGAATGATGG-3' and the Reverse 
primer: 5'- ATTCCTAGCTGGTTTCTGAC -3'. 
Synthesis of the suitable size (385 bp) PCR products 
was confirmed by agarose gel electrophoresis. 
Genotyping was performed by polymerase chain 
reaction–restriction fragment length polymorphism 
(PCR-RFLP). The VEGF (-2578C/A) PCR product was 
digested with restriction endonuclease BglII (sequence 
of restriction site: AGATCT) for 5h at 37°C. The PCR 
fragments of the A/C genotype were digested into 
fragments of 113,272bp and 385bp. AA genotype was 
also digested into two fragments of 113bp and 272 bp 
and CC genotype was digested into a 385-bp product. 
Fragments were analysed on 3% agarose 
electrophoresis gels visualised using a UV-based trans-
illuminator to detect ethidium bromide staining. 
Statistical analysis 
Unconditional logistic regression analysis was 
conducted to estimate adjusted and unadjusted odds 
ratio (OR) and 95% confidence interval (CI) to 
determine association of -2578C/A with the risk of 
CRC. OR and 95% CI were adjusted for age, sex and 
smoking status. In CRC patients, the coloration 
between the clinical pathology features and 
polymorphism were examined using chi-square test. 
Data were considered significant when the statistical p-
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value was <0.05.  All the statistical analyses were 
carried out using SPSS (v.13).  
 
Results 
VEGF genotypes did not deviate from the Hardy–
Weinberg equilibrium among patients or controls 
(p=0.759, p =0.151, respectively for case and controls). 
Table 1 shows the genotype and allelic distributions of 
the -2578C/A polymorphism in cases vs. controls. We 
found no statistically significant association between 
this polymorphism and the risk of colorectal cancer 
(p=0.156, OR=1.224, CI=0.926–1.617). Characteristics 
of patients and control subjects including age, smoking 
habit and gender are summarized in Table1. 
 No significant differences were observed in age or 
smoking between the two groups. Correlation between 
the stage of the disease and genotype was shown in 
Table 2. The genotyping frequency of -2578C/A 




VEGF binding to VEGFR leads to the activation 
of many signalling pathways such as Ras/Raf/MAPK 
which are involved in cell growth, cell proliferation, 
angiogenesis and survival of endothelial cells (37). 
VEGF is a master mediator of vascular permeability 
with a significant role in angiogenesis and metastasis of 
human cancer including colorectal cancer (38). VEGF 
gene is highly polymorphic and at least 30 single-
nucleotide polymorphisms (SNP) in this gene have 
been described in the literature (39-42). Functional 
polymorphisms may influence the expression of a gene 
(29). This effect may be due to only one polymorphism, 
or a combined effect of more than one polymorphism 
(29). It has been shown that polymorphisms located in 
promoter, 5′ and 3′ untranslated regions of the VEGF 
gene have functional influence on VEGF gene 
expression (43-46). In the present study, the VEGF -
2578C/A polymorphism did not alter the risk of 
developing colorectal cancer in our Iranian population 
(p=0.247). However, Park et al. reported a different 
frequency of this genotype in a Korean population (32). 
Similar to our results, Hoffmann et al. have shown no 
association of VEGF gene-2578C/A polymorphism 
with the risk of colorectal cancer in a population 
(p=0.23) (38). Also, in line with our study, results of 
Vidurrent et al. showed a similar distribution (47,48). 
 
Table 1. Characteristics of populations. 
Variables Cases (N=200) Control (N=200) 1P value 
Age (mean ± SD) 58.37±12.998 45.27±13.151  
Gender 
      Female                                               95 (47.5%)                                             115 (57.5%) 
      Male                                                 105 (52.5%)                                              85 (42.5%) 
Smoking 
      Never                                               182 (91.0%)                                              173 (86.5%)                                         0.154 
      Ever                                                  18 (9.0%)                                                  27 (13.5%) 
Genotype 
      CC 
      AC  
      AA 
 
              45 (22.5%) 
              102 (51.0%) 
              53 (26.5%) 
 
                        32 (16.0%) 
                        108 (54.0%) 
                        60 (30.0%) 
 
    
   0.247 
Allele 
      A 
      C 
 
              208 (52.0%) 
              192 (48.0%) 
 
                        228 (57.0%) 
172 (43.0%) 
 
   0.156 
1 Significant change (P value < 0.05) when compared to the control. 
 
 
Table 2. The tumour-stage shows specific distribution of VEGF -2578C/A genotypes among colorectal cancer patients. 
Genotype Stage 0 Stage I Stage II Stage III Stage IV P value 
CC 1 (10.0%) 6 (22.2%) 11 (22.0%) 16 (22.9%) 11 (25.6%)  
AC 5 (50.0%) 14 (51.9%) 26 (52.0%) 36 (51.4%) 21 (48.8%) 0.990 
AA 4 (40.0%) 7 (25.9%) 13 (26.0%) 18 (25.7%) 11 (25.6%)  
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In contrast, Howell et al. and Yang et al. found a 
significant association between -2578C/A 
polymorphism and the risk of breast cancer and 
malignant melanoma in Caucasians (29,49). This 
conflicting result might be due to several reasons 
including ethnic background, genotype distributions, 
environment factor and other clinical factors (50). 
Koukourakis et al. reported the correlation 
between -2578CC genotype and low expression of 
VEGF, while -2578C/A genotype was correlated with 
an increase in the expression of VEGF in lung tumour 
cells (23). Also, Tzanakis et al. reported a significant 
correlation between -2578AA and size of tumour 
(P=0.025), as well as low distinction and progress of 
gastric cancer in a Greek population (P=0.039) (31). In 
the present study, we found no significant differences 
between the cases and controls for the demographic 
data (age, gender and smoking). Moreover, our results 
confirmed observations by Hoffmann et al. (34) and 
Dassoula et al. (51) on demographic features in 
colorectal cancer risk. However, Park et al. reported 
that the frequency of the –2578CA+AA genotype in 
patients was associated with reduced risk for colon 
cancer in women (OR, 0.60; 95% CI, 0.36-0.99; 
p=0.056). Also, frequency of the -2578CA+AA 
genotype was protective against colon cancer in 
patients with proximal colon cancer (OR, 0.55; 95% CI, 
0.31-0.97; p=0.049). Therefore, the effects of VEGF 
genotype may be different in the two genders. There 
was no difference when the data was stratified 
according to gender. According to the previous study 
by Dassoula et al. (51), tumour phenotype can be 
related to the specific organ of origin. Each organ has 
its own individual genotype and phenotype profile. The 
present study had some limitations. The patients were 
recruited from a single centre. Also, no other SNPs in 
this gene were evaluated and associations of other 
genes in angiogenesis with VEGF were not explored. In 
conclusion, we did not find that VEGF -2578C > A 
polymorphism was associated with the risk of CRC in 
Iranian population. Nevertheless, further studies will be 
needed to explore the complicated interaction between 
environmental factors and VEGF -2578C>A 
polymorphism in susceptibility to CRC. This study 
highlights the significant need to take into account 
specific country of origin during SNP analyses. Meta-
data analyses using grouped classifications such as 
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